Dexrazoxane Exposure and Risk of Secondary Acute Myeloid Leukemia in Pediatric Oncology Patients

BACKGROUND: Dexrazoxane may reduce anthracycline-associated cardiotoxicity in pediatric cancer patients. However, concerns of secondary acute myeloid leukemia (AML) have led to restrictions on pediatric dexrazoxane use in Europe. Published data about dexrazoxane-associated secondary AML are limited...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Seif, Alix E., Walker, Dana M., Li, Yimei, Huang, Yuan-Shung V., Kavcic, Marko, Torp, Kari, Bagatell, Rochelle, Fisher, Brian T., Aplenc, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4177031/
https://ncbi.nlm.nih.gov/pubmed/24668949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25043
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados